Shots:
The collaboration will combine AbCellera’s Ab discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and deliver new and transformative therapies to patients
Under the terms of collaboration, both companies will co-develop up to five rare disease therapeutic targets. The collaboration enables Rallybio to expand its pipeline of product candidates, and AbCellera has the option to carry out process development and clinical manufacturing activities
The first program focuses to address the significant unmet therapeutic needs of rare metabolic diseases patients
Ref: Businesswire | Image: AbCellera
